Have library access?
IP:18.97.14.88
  • Journals
  • OpenAccess

Chondromalacia: Etiology, Management Challenges, and Alternative Treatment

Abstracts


In this study, a patient received two local injections of TELOXOME, a novel stem cell-derived agent developed by ContiNew Medical. The injections were administered to the patient's left knee, with the injections separated by 3 weeks. The patient underwent magnetic resonance imaging (MRI) of the knee before and at 6 months after the TELOXOME injections. The MRI scans revealed a significant improvement in chondromalacia following the two TELOXOME injections. This finding indicates that TELOXOME may be an effective treatment option for chondromalacia, especially in cases where traditional treatments have failed.

Keywords

exosome chondromalacia patellae TELOXOME

Read-around